MSC therapy uses mesenchymal stem cells, harvested from sources like bone marrow, fat tissue, or umbilical cord, to treat damaged or inflamed tissues in the body. Rather than rebuilding organs cell by cell, these cells work mostly by releasing a cocktail of signaling molecules that calm inflammation, recruit the body’s own repair systems, and promote new blood vessel growth. Clinical trials have tested MSC therapy across a wide range of conditions, from knee osteoarthritis and heart failure to autoimmune diseases and graft-versus-host disease after bone marrow transplants, with results that are genuinely encouraging but still far from a cure-all.
Where the Cells Come From
Mesenchymal stem cells can be pulled from several tissues in the body, and the source matters more than you might expect. The three most studied origins are bone marrow, adipose (fat) tissue, and umbilical cord blood or cord tissue. A comparative study found that all three sources produce cells with similar surface markers and appearance, but they differ in practical ways. Fat tissue yields MSCs at the highest frequency, and the isolation success rate for both bone marrow and fat is essentially 100%. Umbilical cord blood, by contrast, succeeds only about 63% of the time, and the colonies it produces are fewer. The tradeoff is that cord-blood MSCs proliferate faster and can be cultured for longer periods than bone-marrow MSCs, which have the shortest culture lifespan of the three.1PubMed. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue
Cord tissue MSCs and adipose MSCs have also been directly compared. Both differentiate into bone, cartilage, fat, and neuronal structures, and they share the same surface-marker profile. Cord tissue cells grow faster, but adipose cells form more colonies when seeded at low numbers.2Cytotherapy. Comparison of human mesenchymal stem cells derived from adipose and cord tissue In practice, the choice often hinges on logistics and the condition being treated. Fat tissue is abundant in adults and easy to obtain through liposuction. Cord tissue and cord blood must be collected at birth, but they offer cells from a younger, more proliferative source. Bone marrow remains the most historically studied source and the default in many cardiovascular trials.
How MSCs Actually Work
Early enthusiasm for MSCs centered on the idea that they would physically replace damaged cells by transforming into heart muscle, cartilage, or neurons. That picture has been largely revised. Most of the therapeutic benefit comes not from what MSCs become but from what they release. MSCs secrete a rich mix of growth factors, anti-inflammatory proteins, and tiny membrane-bound packages called extracellular vesicles. This secreted mixture, sometimes called the secretome, stimulates the body’s own tissue-repair processes and tamps down overactive immune responses.3PubMed Central. Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis In wound healing, for example, although MSCs can differentiate inside the wound, the bulk of the benefit appears to come from soluble factors that regulate local cellular responses to injury.4PubMed Central. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair
This “pharmacy rather than building material” model has a few important implications. It means the cells do not need to survive long-term in the recipient to do their job. It also means their effects can potentially be replicated without using living cells at all, a direction researchers are actively pursuing. And it explains why MSCs seem to help in such wildly different conditions: their secreted factors address common denominators like inflammation, poor blood supply, and dysfunctional immune signaling regardless of which organ is involved.
Immune Modulation
One of the most clinically useful properties of MSCs is their ability to dial down immune responses without broadly suppressing the immune system the way a drug like cyclosporine does. MSCs interact with multiple arms of immunity. They inhibit T-cell proliferation, and they also push macrophages from a pro-inflammatory state toward an anti-inflammatory one that secretes the calming cytokine IL-10. That macrophage switch depends in part on a protein called IL-1 receptor antagonist: when MSCs lack that protein, they are less effective at driving the macrophage shift, even though their ability to suppress T cells remains intact.5STEM CELLS. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation
This immunomodulatory capacity is what makes MSCs attractive for graft-versus-host disease, the dangerous condition in which transplanted donor immune cells attack the recipient’s body. No single drug has emerged as an optimal second-line treatment for this complication, but MSC infusions have shown substantial promise across a large number of clinical studies. The cells promote an immunosuppressive environment through multiple mechanisms simultaneously, including secreted proteins, transfer of mitochondria to damaged cells, and release of exosomes carrying regulatory RNA. Response rates have varied across trials, but the safety profile has been consistently favorable.6PubMed Central. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease
Where It Is Being Tested in Humans
Knee Osteoarthritis
Osteoarthritis of the knee is probably the most active testing ground for MSC therapy. A meta-analysis of randomized controlled trials found that injecting MSCs into the knee joint significantly improved pain and function scores at both six and twelve months compared to controls. Subgroup analysis suggested that adipose-derived cells and higher cell doses produced the strongest improvements. Adverse events were no more frequent in the MSC group than in the control group.7PubMed Central. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials The catch is that while pain relief and functional gains are real, full repair of cartilage defects has not been achieved. The injections help, but they may not be sufficient to fully regenerate damaged joint surfaces.8PubMed Central. Clinical Trials with Mesenchymal Stem Cell Therapies for Osteoarthritis: Challenges in the Regeneration of Articular Cartilage Still, the cumulative clinical evidence supports the idea that MSC injections can improve quality of life and may help delay or avoid knee replacement surgery.9Biomolecules & Therapeutics. Intra-Articular Injection of Stem Cells for the Regeneration of Knee Joint Cartilage: a Therapeutic Option for Knee Osteoarthritis
Heart Failure and Cardiovascular Disease
MSCs are the most widely used cell type in stem cell therapy for advanced heart failure, partly because they are easy to isolate and expand in the lab.10Regenerative Therapy. A comprehensive review of clinical trials and progress in stem cell therapies for advanced heart failure Multiple clinical trials going back to 2005 have assessed MSC infusions after heart attacks and in chronic ischemic cardiomyopathy. The results have been broadly positive for safety: no tumor development has been reported across these trials, and patients generally tolerate the cells well. Some trials have shown improvements in heart function and quality of life, particularly with intravenous infusions of umbilical cord MSCs in patients with chronic stable heart failure.11Cell Death & Disease. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases The POSEIDON trial compared autologous MSCs (from the patient’s own marrow) with allogeneic MSCs (from a donor) in patients with ischemic cardiomyopathy. Both types were safe and reduced infarct size by about a third on average. The autologous group showed a clearer improvement in walking capacity, gaining roughly 66 meters on a six-minute walk test at twelve months, while the allogeneic group’s gain was smaller and not statistically significant on its own.12JAMA. Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial
Autoimmune and Inflammatory Diseases
A systematic review and meta-analysis of randomized trials found that MSC transplantation significantly improved symptoms in several autoimmune and rheumatic conditions. In systemic lupus erythematosus, disease activity scores dropped substantially. In inflammatory bowel disease, clinical efficacy roughly doubled compared to controls. The review also reported improvements in spondyloarthritis and rheumatoid arthritis, though the data in some of these conditions is still thin enough that larger trials are needed.13PubMed Central. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials
The Lung Trap and How Delivery Route Matters
One of the underappreciated challenges of MSC therapy is getting the cells where they need to go. When MSCs are infused intravenously, the majority of them get trapped in the lungs on first pass. The pulmonary capillary bed acts like a filter, and because MSCs are relatively large cells, a therapeutically questionable number actually reach the arterial system and, by extension, the target organ.14PubMed Central. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect This is one reason why direct injection, whether into a joint, into heart muscle, or into spinal fluid, is preferred for many conditions. For knee osteoarthritis, intra-articular injection places cells right at the site of damage. For heart failure, transendocardial injection delivers them into the heart wall.
Intravenous delivery is not useless, though. In conditions like graft-versus-host disease or systemic autoimmune flares, the immune modulation provided by MSCs may not require the cells to physically reach a specific organ. The signaling factors they release from the lungs and other sites of entrapment can still enter the circulation and dampen immune activity systemically. The route, in other words, should match the therapeutic goal.
Cell-Free Therapy With Exosomes
If MSCs work mainly by what they secrete, a logical next step is to skip the cells entirely and use only the secreted products. That idea has driven a growing field around MSC-derived exosomes, which are nanoscale vesicles that carry RNA, proteins, and other bioactive molecules. These exosomes appear to reproduce many of the same effects as live MSCs, including anti-inflammatory, tissue-repair, and blood-vessel-promoting activity.15PubMed Central. Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine Compared to live cell infusions, exosomes offer lower immunogenicity and a better safety profile, since they cannot replicate or transform.16PubMed Central. Mesenchymal Stem-Cell-Derived Exosomes and MicroRNAs: Advancing Cell-Free Therapy in Systemic Sclerosis
The challenge is making exosome-based therapies consistently. The quality, reproducibility, and potency of exosome production must be carefully controlled, in the same way that live MSC production must meet these standards.17PubMed. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy Exosome therapy is still largely preclinical, but it is one of the more promising directions for moving MSC-like benefits into something closer to an off-the-shelf product.
Safety Profile So Far
The safety data on MSC therapy is more reassuring than many people expect, given how cautious the regulatory environment around stem cells is. A systematic review and meta-analysis of clinical trials found no significant difference in tumor formation between MSC-treated patients and controls.18PLOS ONE. Safety of Cell Therapy with Mesenchymal Stromal Cells: A Systematic Review and Meta-Analysis of Clinical Trials A separate systematic review specifically focused on the question of malignant transformation found no evidence that MSC treatment increases tumor incidence.19Journal of Stem Cells Research Development & Therapy. Mesenchymal Stem Cell Treatment Does Not Result in Tumor Formation: A Systematic Review
One real concern is clotting risk. MSCs express tissue factor on their surface, a molecule that can trigger the coagulation cascade when cells contact blood. This is most relevant during intravenous infusion. Patients receiving IV umbilical cord MSCs showed a transient spike in D-dimer levels, a marker of clotting activity, whereas patients receiving the same cells by intrathecal injection (into spinal fluid, bypassing the bloodstream) did not.20PubMed Central. Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma The procoagulant activity is linked to tissue factor expression on the cell surface, and it is something that researchers and clinicians are increasingly screening for, especially with culture-expanded cells that may express higher levels.21PubMed Central. Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives
Why Some Patients Respond and Others Don’t
Not everyone benefits equally from MSC therapy, and figuring out why is one of the bigger open questions. Part of the variability sits on the patient’s side. A review of 41 studies on adipose-derived stem cells found that increasing age, higher body mass index, diabetes, and prior exposure to radiation therapy or tamoxifen were all associated with decreased proliferation and differentiation potential of the harvested cells.22PubMed Central. Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy When the cells come from the patient themselves (autologous therapy), these factors directly affect the quality of the therapeutic product.
Even when cells come from a healthy donor, patient characteristics can determine outcomes. In a study of umbilical cord MSC therapy for type 2 diabetes, about 60% of patients hit their target blood sugar control at nine weeks. The strongest predictor of response was residual insulin-producing capacity, measured by C-peptide levels. Male patients with lower baseline blood sugar and higher baseline testosterone responded better.23PubMed. Predictive factors that influence the clinical efficacy of umbilical cord-derived mesenchymal stromal cells in the treatment of type 2 diabetes mellitus Identifying these predictive factors before treatment could eventually allow clinicians to select the patients most likely to benefit and avoid futile treatments.
Priming Cells Before Use
Researchers have discovered that you can steer MSC behavior by how you treat the cells before infusing them, a process called priming. Exposing MSCs to low oxygen (hypoxic priming) pushes them toward producing factors that promote tissue repair, making them better suited for acute injuries. Exposing them to inflammatory signals like interferon-gamma ramps up their production of immunosuppressive molecules, which is more useful for chronic immune-driven conditions.24PubMed Central. Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
Combining both strategies at once produces additive effects. Dual interferon-gamma and hypoxia priming markedly enhances T-cell suppression beyond what either treatment achieves alone. The interferon-gamma drives expression of immunosuppressive surface proteins, while hypoxia switches the cells’ metabolism in a way that starves nearby T cells of glucose and generates inhibitory lactate. Together, the effect is stronger than either priming strategy on its own.25Journal of Immunology and Regenerative Medicine. Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms These priming approaches are one way researchers hope to reduce the inconsistency that has dogged MSC trials: rather than accepting whatever the cells naturally do, you tune them for the job at hand.
Manufacturing Headaches
One of the biggest obstacles between promising trial results and widely available MSC therapy is scaling up production while keeping quality consistent. MSCs are living biological products, and they behave unpredictably at scale. Cell aging during expansion, differences between donors, and sensitivity to physical stress in bioreactors all lead to variable potency from batch to batch. This inconsistency has confounded clinical trial readouts, making it hard to tell whether a failed trial reflects a genuinely ineffective therapy or simply a bad batch of cells.26PubMed Central. Bioreactors expansion of human mesenchymal stromal cell therapies: platforms, parameters, challenges and opportunities
Freezing adds another layer of complexity. When MSCs are cryopreserved and thawed for use, viability drops, metabolic activity is impaired, and adhesion potential decreases in the first several hours after thawing. At 24 hours post-thaw, viability recovers and cell death rates fall, but metabolic function and adhesion are still below the level of fresh cells.27PubMed Central. Quantitative assessment of the impact of cryopreservation on human bone marrow-derived mesenchymal stem cells: up to 24 h post-thaw and beyond One approach that seems to help is allowing thawed cells a 24-hour acclimation period in culture before use. Cells given that recovery window show reduced cell death, upregulation of anti-inflammatory and blood-vessel-promoting genes, and more potent T-cell suppression compared to cells used immediately after thawing.28PubMed Central. Cryopreserved mesenchymal stem cells regain functional potency following a 24-h acclimation period Whether clinical protocols will routinely incorporate this kind of recovery step remains to be seen, but it highlights how sensitive MSC products are to handling details that might seem minor.
Scaffolds and Biomaterials
For tissue-engineering applications, injecting free-floating cells is not always the best approach. Researchers have been combining MSCs with hydrogel scaffolds, which are soft, water-rich materials that mimic the structure of natural tissue. These composites can hold cells in place at a defect site and provide a three-dimensional environment that encourages them to function more naturally. The combination of MSCs with a scaffold has shown better outcomes in biological function of injured areas than either the scaffold or the cells used alone.29Hydrogels – From Tradition to Innovative Platforms with Multiple Applications. Mesenchymal Stem/Stromal Cells and Hydrogel Scaffolds for Tissue Engineering This approach is most relevant for structural repairs, such as bone defects, cartilage injuries, or chronic wounds, where you need cells to stay put and organize into functional tissue rather than just release signals and drift away.
Rogue Clinics and What to Watch For
The gap between legitimate research and what is being sold to the public is enormous. Hundreds of clinics worldwide market “stem cell” injections directly to consumers for conditions ranging from aging to autism, often without adequate data on what the injections actually contain, whether the cells are viable, or whether the claimed condition is one that MSCs could plausibly help. These providers make unwarranted claims and sometimes perform risky procedures with preparations whose true content and efficacy are unknown.30PubMed Central. Rogue stem cell clinics Regulatory agencies in many countries have struggled to keep up. The line between a legitimate clinical trial, a compassionate-use program, and an outright scam can be hard for patients to distinguish. Anyone considering MSC therapy outside of a registered clinical trial should ask whether the treatment has been tested in randomized controlled trials for their specific condition, whether the clinic can provide batch-testing data for the cell product, and whether an independent ethics review has approved the protocol. The absence of any of those is a red flag.
Veterinary Applications
MSC therapy has actually moved further into routine use in veterinary medicine than in human medicine. Stem cells are most commonly used clinically in veterinary settings for musculoskeletal injuries in horses and dogs.31PubMed Central. Stem cells in veterinary medicine Racehorses with tendon injuries and dogs with hip dysplasia or osteoarthritis have been treated with MSC injections for years, and the regulatory bar is lower than for human therapies. These veterinary applications have served as a useful real-world testing ground, generating outcome data on joint and tendon repair that, while not directly transferable to humans, has helped refine cell-processing techniques and injection protocols that eventually inform human clinical trials. If you have a dog with chronic joint pain, MSC therapy is already a conversation your vet may initiate, which gives you a sense of how far ahead the veterinary field is on this front.